Brief: Brii Biosciences Updates On Development Of VIR-3434
04/07/2022 02:30
July 4 (Reuters) - Brii Biosciences Ltd 2137.HK :
* EXERCISED ITS OPTION TO IN-LICENSE VIR-3434 FOR ITS
EXCLUSIVE
DEVELOPMENT AND COMMERCIALIZATION RIGHTS IN GREATER CHINA
Source text for Eikon: ID:nHKS9zc1Zs
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR